Effects of leflunomide on immune responses and models of inflammation

Springer Seminars in Immunopathology

Volumn 14, Issue 4, 1993, Pages 381-394

  Bartlett, Robert R ^a   Anagnostopulos, Hristo ^a   Zielinski, Thomas ^b   Mattar, Thomas ^b   Schleyerbach, Rudolph ^a  

^a SANOFI   (France)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; INDOMETACIN; LEFLUNOMIDE; PHENYLBUTAZONE; PREDNISOLONE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTHRITIS; AUTOIMMUNITY; DRUG THERAPY; GRAFT REJECTION; INFLAMMATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GRAFT REJECTION; HUMAN; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; ISOXAZOLES; MICE; PROTEIN-TYROSINE KINASE; RATS;

EID: 0027238470     PISSN: 03444325     EISSN: 14322196     Source Type: Journal    
DOI: 10.1007/BF00192310     Document Type: Article

References (35)

1. The challenge: how good a model of MS is EAE today?
2. Immunopharmacological profile of HWA486, a novel isoxazol derivative. II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A
3. Cyclophosphamide
4. Immunopharmacological profile of a novel isoxazol derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat
5. Immunologic, histologic and ultrastructural studies in autoimmune MRL/L mice
6. Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease
7. Leflunomide (HWA 486): a novel immunorestoring drug
8. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
9. Binding of G-CSF, GM-CSF, tumor necrosis factor-α and γ-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein
10. Joint destruction in various arthritic diseases
11. IL-1 induce rapid phosphorylation of the IL-1 receptor
12. Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology
13. Proteoglycan-specific autoreactive antibodies and T-lymphocytes in experimental arthritis and human rheumatoid joint disease
14. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide
15. Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity
16. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis
17. A spontaneous rheumatoid arthritis-like disease In MRL/L mice
18. Prevention of kidney and skin graft rejection in rats by lefiunomide, a new immunomodulating agent
19. Evaluation of the ability of anti-rheumatic drugs to suppress hyperaemia and increased vascular permeability
20. Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides
21. Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor β is tyrosine phosphorylated
22. Effects of lefiunomide on glomerulonephritis induced by antibasement membrane antibody in rats
23. Autoimmune MRL/lpr mice sera contain IgG with interleukin 3-like activity
24. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis
25. B cell stimulatory factor-1 interleukin 4
26. IL-3-induced activation of protein kinases in the mast cell/megakaryocyte R6-Xe. 4 line
27. The use of a standardized adjuvant arthritis assay to differentiate between antiinflammatory and immunosuppressive agents
28. Disease modifying activity of HWA486 on the development of SLE in MRL/1 mice
29. The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
30. Distinction between T helper cell replacing factor (TRF) and T cell growth factor (TCGF)
31. Etiopathogenesis of murine SLE
32. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats
33. Epidermal growth factor and related molecules
34. Growth factor receptor tyrosine kinases